EUVIMEDEUVIMED entdecken
Open Access

An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations

Olivia M Swanson iD, Qianyi E Zhang iD, Elizabeth Van Itallie iD, Ming Tian iD, Alecia R Brown, Caitlin Harris iD, Anyway Brenda Kapingidza, Brianna Rhodes iD, Lena M Smith iD, Sravani Venkatayogi iD, Kenneth Cronin iD, McKenzie Frazier und 17 weitere

Science Translational Medicine · 08.01.2025 · 17 (780)

DOI: 10.1126/scitranslmed.adr2218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 08.01.2025. Verfasst von Olivia M Swanson und 28 weiteren Autor:innen. Beteiligte Einrichtung: Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Mutation, Antibodies, Neutralizing, HIV Antibodies. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition of somatic mutations. Because HIV bnAbs contain mutations in their B cell receptors (BCRs) that are rarely generated during conventional B cell maturation, HIV vaccine immunogens must robustly engage and expand B cells with BCRs that contain these improbable mutations. Here, we engineered an immunogen that activates diverse precursors of an HIV V3-glycan bnAb and promotes their acquisition of a functionally critical improbable mutation. This immunogen was validated biochemically, structurally, and in three different humanized immunoglobulin mouse models that were designed to test HIV immunogens. These results provide a blueprint for rationally designing priming immunogens that explicitly target the elicitation of antibodies with functional yet improbable mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationAntibodies, NeutralizingHIV AntibodiesHumansAnimalsMiceAIDS VaccinesHIV-1B-LymphocytesHIV Infections

Substanzen

Antibodies, NeutralizingHIV AntibodiesAIDS Vaccines

Autor:innen und Institutionen

  • Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Boston Children's Hospital, Harvard Medical School and HHMI, Boston, MA 02115, USA.
  • Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Microbiology and Molecular Genetics, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.

ORCID-Profile: Olivia M Swanson, Qianyi E Zhang, Elizabeth Van Itallie, Ming Tian, Caitlin Harris, Brianna Rhodes, Lena M Smith, Sravani Venkatayogi, Kenneth Cronin, Rob Parks, Jillian Davis, Kelly McGovern, Derek Cain, S Munir Alam, Kevin Wiehe, Kevin O Saunders, Priyamvada Acharya, Barton F Haynes, Mihai L Azoitei

Förderung

  • NIAID NIH HHS

Zitieren

APA

Swanson, O. M., Zhang, Q. E., Van Itallie, E., Tian, M., Brown, A. R., Harris, C., Kapingidza, A. B., Rhodes, B., Smith, L. M., Venkatayogi, S., Cronin, K., Frazier, M., Parks, R., Bar, M., Jiang, C., Martin Beem, J. S., Cheng, H. L., Davis, J., McGovern, K., …, & Azoitei, M. L. (2025). An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations. Science Translational Medicine, 17(780). https://doi.org/10.1126/scitranslmed.adr2218

Vancouver

Swanson OM, Zhang QE, Van Itallie E, Tian M, Brown AR, Harris C, et al. An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations. Science Translational Medicine. 2025;17(780). doi:10.1126/scitranslmed.adr2218

BibTeX
@article{Swanson2025,
  author = {Swanson, Olivia M and Zhang, Qianyi E and Van Itallie, Elizabeth and Tian, Ming and Brown, Alecia R and Harris, Caitlin and Kapingidza, Anyway Brenda and Rhodes, Brianna and Smith, Lena M and Venkatayogi, Sravani and Cronin, Kenneth and Frazier, McKenzie and Parks, Rob and Bar, Maggie and Jiang, Chuancang and Martin Beem, Joshua S and Cheng, Hwei-Ling and Davis, Jillian and McGovern, Kelly and Newman, Amanda and Edwards, Robert J and Cain, Derek and Alam, S Munir and Wiehe, Kevin and Saunders, Kevin O and Acharya, Priyamvada and Alt, Fred and Haynes, Barton F and Azoitei, Mihai L},
  title = {An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {780},
  doi = {10.1126/scitranslmed.adr2218}
}
Kostenlos starten →